Advances in Cervical Cancer Classification: Comparing Deep Learning Models for Enhanced Screening Accuracy

By João L. Carapinha

February 3, 2025

A recent article provides a comprehensive comparison of 16 deep learning models focused on cervical cancer classification using transfer learning from pap smear images. The study utilized two publicly available datasets, Herlev and SIPaKMeD, and evaluates the performance of various pre-trained CNN models such as VGG16, VGG19, ResNet series, DenseNet series, MobileNet, XceptionNet, InceptionV3, and InceptionResNetV2. The results reveal that models like VGG16 and ResNet50 achieved high accuracy rates, outperforming traditional classification methods and existing state-of-the-art approaches.

Study Details

The study highlighted that VGG16 and ResNet50 models achieved the highest accuracy rates on the SIPaKMeD and Herlev datasets, respectively. For instance, VGG16 achieved an accuracy of 99.95% for 2-class classification on the SIPaKMeD dataset, while ResNet50 reached an accuracy of 95.10% for 2-class classification on the Herlev dataset. The application of data augmentation techniques alongside transfer learning significantly enhanced the models’ performance and generalizability. Data augmentation expanded the dataset size, whereas transfer learning utilized pre-trained models to adapt efficiently to new tasks. The proposed method outperformed existing state-of-the-art methods in terms of accuracy and F1-score, showcasing its superiority in cervical cancer classification.

Cost-effectiveness of AI-enabled Cervical Cancer Classification

The adoption of deep learning-based computer-aided detection (CAD) systems for cervical cancer classification could be cost-effective over time. These systems reduce the reliance on manual screening, which is labor-intensive and requires highly trained personnel. Automated screening can also decrease the time and resources needed for diagnosis, potentially lowering healthcare costs. In resource-limited settings, deep learning models can provide substantial benefits. They can help address the shortage of trained personnel, improving the accuracy of cervical cancer diagnoses and enhancing healthcare outcomes. The high accuracy of these models in diagnosing cervical cancer at early stages can lead to improved treatment outcomes. Early detection minimizes the need for invasive and costly treatments, yielding significant economic and health benefits.

These deep learning models can help reduce mortality rates. Early detection and effective treatment are crucial to mitigating deaths from cervical cancer. Also, the integration of these models into public health policies could strengthen national cervical cancer screening programs. This includes training healthcare professionals in using these systems and ensuring the necessary infrastructure supports their implementation. Further research is needed though and collaboration to compile larger, diverse datasets and address current model limitations. This collective effort can lead to the development of more robust and generalizable models applicable across different healthcare settings.

Reference url

Recent Posts

allopurinol Marfan syndrome orphan
       

Allopurinol Designated an Orphan Drug for Marfan Syndrome

🌟 What does the EMA’s orphan drug designation for allopurinol mean for those impacted by Marfan syndrome?

This groundbreaking move highlights a significant step forward in tackling rare diseases, offering hope to patients with limited treatment options. Allopurinol, traditionally used for gout, shows promise in addressing life-threatening aortic complications associated with Marfan syndrome, thanks to its antioxidant properties.

Dive into the implications of this development for healthcare innovation, patient access, and the future of rare disease treatment!

#SyenzaNews #HealthEconomics #Innovation #MarketAccess

marstacimab hemophilia B
                

NICE’s Approval of Marstacimab for Hemophilia B: Transforming Treatment Landscapes and Economic Implications

💡 Are we witnessing a paradigm shift in hemophilia treatment?

The recent recommendation from NICE for marstacimab as a novel therapy for severe hemophilia B is a game-changer. With its ability to provide effective prophylaxis while potentially lowering treatment costs, this could reshape patient care and health economics in this space.

Dive into the implications this has for patients and healthcare providers, and why marstacimab’s approval could be a pivotal moment for hemophilia management.

Explore the full article for deeper insights!

#SyenzaNews #HealthEconomics #HealthcareInnovation #MarketAccess

HPV-related cancer trends
    

HPV-Related Cancer Trends in South Africa 2011-2021

🌍 Are we witnessing a rise in HPV-related cancer in South Africa?

A recent analysis of data from the South African National Cancer Registry highlights concerning trends: while cervical cancer rates are declining, there’s an alarming rise in non-cervical anogenital cancers. This underscores the urgent need for enhanced cancer prevention and access to efficient healthcare services in the country.

Dive into the findings and explore the implications for health systems and policies.

#SyenzaNews #HealthEconomics #HealthcareInnovation #GlobalHealth

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.